Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.1 USD | -4.67% | -49.55% | -74.06% |
May. 10 | Baird Adjusts Cerence Price Target to $8 From $15, Maintains Neutral Rating | MT |
May. 10 | Wedbush Adjusts Cerence's Price Target to $9 From $21, Keeps Neutral Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-74.06% | 224M | C | ||
+10.02% | 3,082B | C+ | ||
+8.25% | 84.92B | B | ||
+4.44% | 78.23B | B+ | ||
-14.19% | 54.06B | B+ | ||
-23.14% | 46.79B | B- | ||
+21.64% | 42.68B | D+ | ||
+59.16% | 37.28B | D+ | ||
-10.56% | 24.89B | C+ | ||
+18.21% | 21.93B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRNC Stock
- Ratings Cerence Inc.